Log in or Sign up for Free to view tailored content for your specialty!
Hematology News
Incidence of cancer-associated thrombosis remains high over time, varies with therapy
Incidence of venous thromboembolism remained high among patients with cancer even as the treatment landscape has evolved over the past 16 years, according to data published in JAMA Network Open.
Concizumab prophylaxis significantly reduces bleeding events for people with hemophilia
Prophylactic concizumab conferred significant reductions in treated spontaneous and traumatic bleeds among patients with hemophilia A or B without inhibitors, a primary analysis of the randomized phase 3 explorer8 study showed.
Log in or Sign up for Free to view tailored content for your specialty!
Once-weekly Altuviiio offers bleed protection for children with severe hemophilia A
Once-weekly prophylaxis with a high-sustained factor VIII replacement therapy exhibited effective bleed protection for children with severe hemophilia A, according to the agent’s manufacturer.
Iron deficiency common among girls, young women
Iron deficiency appeared common among a cohort of U.S. females aged 12 years to 21 years, with an overall prevalence of nearly 40%, according to study results published in a research letter in JAMA.
Peripheral catheter system recalled due to potential for separation, leakage
The FDA has designated a recall of a peripheral catheter system as class I, the most serious kind.
Biopsychosocial model could improve quality of care for patients with sickle cell disease
Sickle cell disease is known to be associated with severe pain, but the current care model primarily focuses on acute vaso-occlusive pain.
Adults with atopic dermatitis face slightly elevated venous thromboembolism risk
An increased rate of venous thromboembolism is associated with atopic dermatitis in adults, although that increased risk is small, according to a study.
Andexanet alfa postmarketing trial stopped early due to superior efficacy
AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.
Marstacimab reduces bleeding in hemophilia A or B
Marstacimab reduced annualized bleeding rate compared with prophylaxis and on-demand IV regimens for patients with hemophilia A or B, according to the agent’s manufacturer.
Milvexian granted fast track designation for prevention of thrombotic events
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read